Glucagon-like peptide 1 (GLP-1) drugs, such as Ozempic, are intended for type 2 diabetes patients and people with obesity, ...

Glucagon-like peptide 1 (GLP-1) drugs, such as Ozempic, are intended for type 2 diabetes patients and people with obesity, ...

With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is ...

timing and frequency of germline and somatic testing for HRRm, and line of therapy where novel hormonal therapies and/or PARP ...

Caris Life Sciences ® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced ...

In one, recurrence occurred in two subsequent pregnancies, presumably due to germline mosaicism. Conclusions De novo mtDNA point mutations are a common cause of mtDNA disease. Recurrence risk is low.

genetic epilepsy with febrile seizures plus spectrum (MONDO:0800489) persistent truncus arteriosus, GATA6-related, cattle (MONDO:1012936) progressive retinal atrophy, SLC4A3-related, dog ...

FoundationOne®Germline and FoundationOne®Germline More, in the United States to identify genetic variants associated with hereditary cancers and can be used by healthcare providers to understand ...

Causal to the syndrome are germline mutations of the MEN1 tumor-suppressor gene. Identification of gene-mutation carriers has enabled presymptomatic diagnosis and treatment of MEN1-related lesions.

Background PARP inhibitors (PARPi) have been licensed for the maintenance therapy of patients with metastatic pancreatic cancer carrying pathogenic germline BRCA1/2 mutations. However ... determines ...

Background De novo mutations (DNMs) are linked with many severe early-onset disorders ranging from rare congenital malformation to intellectual disability. Conventionally, DNMs are considered to have ...